{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:48:09Z","timestamp":1790200089538,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Science and Technology Development Projects of Jining","award":["2016-56-25"],"award-info":[{"award-number":["2016-56-25"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81720108002"],"award-info":[{"award-number":["81720108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Province\u2019s Medical Elite Program","award":["ZDRCA2016022"],"award-info":[{"award-number":["ZDRCA2016022"]}]},{"name":"Jiangsu Provincial Special Program of Medical Science","award":["BE2017751"],"award-info":[{"award-number":["BE2017751"]}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"crossref","award":["2018ZX09734007"],"award-info":[{"award-number":["2018ZX09734007"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key research and development projects of Jining","award":["2018SMNS008 and 2019SMNS007"],"award-info":[{"award-number":["2018SMNS008 and 2019SMNS007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To explore the clinical features and immunological mechanisms of Castleman disease (CD) complicated with autoimmune diseases (AID).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We explored the prevalence and clinical manifestations of CD complicated with AID by reviewing clinical, pathological, and laboratory data of 40 CD patients retrospectively, and then explored abnormal immune mechanisms in the co-existence of the two entities by monitoring lymphocyte subsets in peripheral blood.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Paraneoplastic pemphigus, autoimmune hemolytic anemia, Sjogren\u2019s syndrome, myasthenia gravis, and psoriasis were found to be coexisted with CD in 9\/40 (22.5%) patients with different sequence of onset. No bias in the clinical and histological type of CD was observed for the occurrence of AID. CD patients with AID were more likely to have skin and\/or mucous membrane damage and pulmonary complications, and presented elevated erythrocyte sedimentation rate, hypergammaglobulinemia, and positive autoantibodies than those without AID (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Deregulated cellular and innate immune responses as indicated by decreased CD3<jats:sup>+<\/jats:sup> T cells and increased natural killer cells were observed in peripheral blood of CD patients with AID (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). UCD patients with AID were successfully treated with surgery and immunosuppressive therapy. MCD complicated by AID relieved with immunosuppressors, cytotoxic chemotherapy, and rituximab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Systemic inflammation\/immunological abnormalities and organ dysfunction were associated with the occurrence of AID in CD. Impairment of cellular and innate immunity may be a candidate etiology for the coexistence of the two entities.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-020-03494-2","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T14:22:40Z","timestamp":1612621360000},"page":"2107-2115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases"],"prefix":"10.1007","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-9727","authenticated-orcid":false,"given":"Dao-Ping","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Yuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"3494_CR1","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/art.27584","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M\u00e9nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588. https:\/\/doi.org\/10.1002\/art.27584","journal-title":"Ann Rheum Dis"},{"key":"3494_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/ard.48.4.326","volume":"48","author":"E Ben-Chetrit","year":"1989","unstructured":"Ben-Chetrit E, Flusser D, Okon E, Ackerman Z, Rubinow A (1989) Multicentric Castleman\u2019s disease associated with rheumatoid arthritis: a possible role of hepatitis B antigen. Ann Rheum Dis 48:326\u2013330. https:\/\/doi.org\/10.1136\/ard.48.4.326","journal-title":"Ann Rheum Dis"},{"key":"3494_CR3","doi-asserted-by":"publisher","first-page":"e5022","DOI":"10.7759\/cureus.5022","volume":"11","author":"SH Bin Waqar","year":"2019","unstructured":"Bin Waqar SH, Khan AA, Mohiuddin O, Rehan A (2019) Paraneoplastic pemphigus with underlying Castleman\u2019s disorder: a rare report with literature review. Cureus 11:e5022. https:\/\/doi.org\/10.7759\/cureus.5022","journal-title":"Cureus"},{"key":"3494_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4314\/gmj.v52i1.9","volume":"52","author":"YA Dei-Adomakoh","year":"2018","unstructured":"Dei-Adomakoh YA, Quarcoopome L, Abrahams AD, Segbefia CI, Dey DI (2018) Sjogren\u2019s and plasma cell variant Castleman disease: a case report. Ghana Med J 52:61\u201365. https:\/\/doi.org\/10.4314\/gmj.v52i1.9","journal-title":"Ghana Med J"},{"key":"3494_CR5","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2019000931","volume":"135","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC (2020) Overview of Castleman disease. Blood 135:1353\u20131364. https:\/\/doi.org\/10.1182\/blood.2019000931","journal-title":"Blood"},{"key":"3494_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.hoc.2017.09.002","volume":"32","author":"DC Fajgenbaum","year":"2018","unstructured":"Fajgenbaum DC, Shilling D (2018) Castleman disease pathogenesis. Hematol Oncol Clin N Am 32:11\u201321. https:\/\/doi.org\/10.1016\/j.hoc.2017.09.002","journal-title":"Hematol Oncol Clin N Am"},{"key":"3494_CR7","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1182\/blood-2013-12-545087","volume":"123","author":"DC Fajgenbaum","year":"2014","unstructured":"Fajgenbaum DC, Rhee FV, Nabel CS (2014) HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 123:2924\u20132933. https:\/\/doi.org\/10.1182\/blood-2013-12-545087","journal-title":"Blood"},{"key":"3494_CR8","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","volume":"129","author":"DC Fajgenbaum","year":"2017","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RSM, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya A, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Foss\u00e5 A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, Rhee FV, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KSJ, Lim MS (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood 129:1646\u20131657. https:\/\/doi.org\/10.1182\/blood-2016-10-746933","journal-title":"Blood"},{"key":"3494_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","volume":"36","author":"MK Hehir","year":"2018","unstructured":"Hehir MK, Silvestri NJ (2018) Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin 36:253\u2013260. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.002","journal-title":"Neurol Clin"},{"key":"3494_CR10","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3324\/haematol.2010.036152","volume":"96","author":"K Hodgson","year":"2011","unstructured":"Hodgson K, Ferrer G, Montserrat E, Moreno C (2011) Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica 96:752\u2013761. https:\/\/doi.org\/10.3324\/haematol.2010.036152","journal-title":"Haematologica"},{"key":"3494_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.5761\/atcs.cr.12.02165","volume":"20","author":"K Ishikawa","year":"2014","unstructured":"Ishikawa K, Kato T, Aragaki M, Ohbuchi T, Kimura S, Matsui Y, Kaji M (2014) A case of Castleman\u2019s disease with myasthenia gravis. Ann Thorac Cardiovasc Surg 20:585\u2013588. https:\/\/doi.org\/10.5761\/atcs.cr.12.02165","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"3494_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40257-016-0235-z","volume":"18","author":"S Kartan","year":"2017","unstructured":"Kartan S, Shi VY, Clark AK, Chan LS (2017) Paraneoplastic pemphigus and autoimmune blistering diseases associated with neoplasm: characteristics, diagnosis, associated neoplasms, proposed pathogenesis, treatment. Am J Clin Dermatol 18:105\u2013126. https:\/\/doi.org\/10.1007\/s40257-016-0235-z","journal-title":"Am J Clin Dermatol"},{"key":"3494_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/1097-0142(197203)29:3<670::aid-cncr2820290321>3.0.co;2-#","volume":"29","author":"AR Keller","year":"1972","unstructured":"Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670\u2013683. https:\/\/doi.org\/10.1002\/1097-0142(197203)29:3<670::aid-cncr2820290321>3.0.co;2-#","journal-title":"Cancer"},{"key":"3494_CR14","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T (2010) IL-6: regulator of Treg\/Th17 balance. Eur J Immunol 40:1830\u20131835. https:\/\/doi.org\/10.1002\/eji.201040391","journal-title":"Eur J Immunol"},{"key":"3494_CR15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1046\/j.1440-1827.2000.01052.x","volume":"50","author":"M Kojima","year":"2000","unstructured":"Kojima M, Nakamura S, Morishita Y, Itoh H, Yoshida K, Ohno Y, Oyama T, Asano S, Joshita T, Mori S, Suchi T, Masawa N (2000) Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: a clinicopathological and immunohistological study of 21 cases. Pathol Int 50:304\u2013312. https:\/\/doi.org\/10.1046\/j.1440-1827.2000.01052.x","journal-title":"Pathol Int"},{"key":"3494_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopha.2006.09.004","volume":"60","author":"M Kojima","year":"2006","unstructured":"Kojima M, Motoori T, Nakamura S (2006) Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients. Biomed Pharmacother 60:663\u2013672. https:\/\/doi.org\/10.1016\/j.biopha.2006.09.004","journal-title":"Biomed Pharmacother"},{"key":"3494_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.5090\/kjtcs.2012.45.3.199","volume":"45","author":"SK Lee","year":"2012","unstructured":"Lee SK, Kim DH, Son BS (2012) Castleman\u2019s disease with myasthenia gravis. Korean J Thorac Cardiovasc Surg 45:199\u2013201. https:\/\/doi.org\/10.5090\/kjtcs.2012.45.3.199","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"3494_CR18","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","volume":"3","author":"AY Liu","year":"2016","unstructured":"Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, Rhee FV, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC (2016) Idiopathic multicentric Castleman\u2019s disease: a systematic literature review. Lancet Haematol 3:e163-175. https:\/\/doi.org\/10.1016\/S2352-3026(16)00006-5","journal-title":"Lancet Haematol"},{"key":"3494_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/bjh.14152","volume":"178","author":"J London","year":"2017","unstructured":"London J, Boutboul D, Agbalika F, Coppo P, Veyradier A, G\u00e9rard L, Oksenhendler E, Azoulay E, Galicier L (2017) Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease. Br J Haematol 178:486\u2013488. https:\/\/doi.org\/10.1111\/bjh.14152","journal-title":"Br J Haematol"},{"key":"3494_CR20","first-page":"ECR03","volume":"89","author":"GD Marchi","year":"2004","unstructured":"Marchi GD, Vita SD, Fabris M, Scott CA, Ferraccioli G (2004) Systemic connective tissue disease complicated by Castleman\u2019s disease: report of a case and review of the literature. Haematologica 89:ECR03","journal-title":"Haematologica"},{"key":"3494_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/BOR.0b013e32834db525","volume":"24","author":"TW Muskardin","year":"2012","unstructured":"Muskardin TW, Peterson BA, Molitor JA (2012) Castleman disease and associated autoimmune disease. Curr Opin Rheumatol 24:76\u201383. https:\/\/doi.org\/10.1097\/BOR.0b013e32834db525","journal-title":"Curr Opin Rheumatol"},{"key":"3494_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/j.1365-2133.2003.05659.x","volume":"149","author":"OV Nikolskaia","year":"2003","unstructured":"Nikolskaia OV, Nousari CH, Anhalt GJ (2003) Paraneoplastic pemphigus in association with Castleman\u2019s disease. Br J Dermatol 149:1143\u20131151. https:\/\/doi.org\/10.1111\/j.1365-2133.2003.05659.x","journal-title":"Br J Dermatol"},{"key":"3494_CR23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/ajh.20283","volume":"78","author":"EM Ocio","year":"2005","unstructured":"Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, Castilla C, Blanco OJ, Caballero D, Miguel JFS (2005) Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol 78:302\u2013305. https:\/\/doi.org\/10.1002\/ajh.20283","journal-title":"Am J Hematol"},{"key":"3494_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5414\/cnp68171","volume":"68","author":"M Ogita","year":"2007","unstructured":"Ogita M, Hoshino J, Sogawa Y, Sawa N, Katori H, Takemoto F, Ubara Y, Hara S, Miyakoshi S, Takaichi K (2007) Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol 68:171\u2013176. https:\/\/doi.org\/10.5414\/cnp68171","journal-title":"Clin Nephrol"},{"key":"3494_CR25","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM,\u00a0Alarc\u00f3n GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, S\u00e1nchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Vollenhoven RFV, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, Magder LS (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677\u20132686. https:\/\/doi.org\/10.1002\/art.34473","journal-title":"Arthritis Rheum"},{"key":"3494_CR26","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","volume":"13","author":"SK Raychaudhuri","year":"2014","unstructured":"Raychaudhuri SK, Maverakis E, Raychaudhuri SP (2014) Diagnosis and classification of psoriasis. Autoimmun Rev 13:490\u2013495. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.008","journal-title":"Autoimmun Rev"},{"key":"3494_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1365-4632.2009.03995.x","volume":"48","author":"VN Sehgal","year":"2009","unstructured":"Sehgal VN, Srivastava G (2009) Paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol 48:162\u2013169. https:\/\/doi.org\/10.1111\/j.1365-4632.2009.03995.x","journal-title":"Int J Dermatol"},{"key":"3494_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/17474086.1.2.189","volume":"1","author":"P S\u00e8ve","year":"2008","unstructured":"S\u00e8ve P, Philippe P, Dufour JF, Broussolle C, Michel M (2008) Autoimmune hemolytic anemia: classification and therapeutic approaches. Expert Rev Hematol 1:189\u2013204. https:\/\/doi.org\/10.1586\/17474086.1.2.189","journal-title":"Expert Rev Hematol"},{"key":"3494_CR29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3238\/arztebl.2017.0354","volume":"114","author":"AL Stefanski","year":"2017","unstructured":"Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, D\u00f6rner T (2017) The diagnosis and treatment of Sjogren\u2019s syndrome. Dtsch Arztebl Int 114:354\u2013361. https:\/\/doi.org\/10.3238\/arztebl.2017.0354","journal-title":"Dtsch Arztebl Int"},{"key":"3494_CR30","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.2169\/internalmedicine.2989-19","volume":"58","author":"S Tabata","year":"2019","unstructured":"Tabata S, Higuchi T, Tatsukawa S, Narimatsu K, Takeo H, Matsukuma S, Ito T (2019) Idiopathic multicentric Castleman disease with autoimmune hemolytic anemia and production of anti-drug antibody against tocilizumab. Intern Med 58:3313\u20133318. https:\/\/doi.org\/10.2169\/internalmedicine.2989-19","journal-title":"Intern Med"},{"key":"3494_CR31","doi-asserted-by":"publisher","first-page":"e12291","DOI":"10.1097\/MD.0000000000012291","volume":"97","author":"L Wang","year":"2018","unstructured":"Wang L, Chen H, Shi J, Tang H, Li H, Zheng WJ, Zhang FC (2018) Castleman disease mimicking systemic lupus erythematosus: a case report. Medicine (Baltimore) 97:e12291. https:\/\/doi.org\/10.1097\/MD.0000000000012291","journal-title":"Medicine (Baltimore)"},{"key":"3494_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.hoc.2017.09.003","volume":"32","author":"K Yoshizaki","year":"2018","unstructured":"Yoshizaki K, Murayama S, Ito H, Koga T (2018) The role of interleukin-6 in Castleman disease. Hematol Oncol Clin N Am 32:23\u201336. https:\/\/doi.org\/10.1016\/j.hoc.2017.09.003","journal-title":"Hematol Oncol Clin N Am"},{"key":"3494_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000328426","volume":"126","author":"A Yuzuriha","year":"2011","unstructured":"Yuzuriha A, Saitoh T, Koiso H, Mitsui T, Uchiumi H, Yokohama A, Handa H, Kojima M, Tsukamoto N, Karaswa M, Murakami H, Nojima Y (2011) Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol 126:147\u2013150. https:\/\/doi.org\/10.1159\/000328426","journal-title":"Acta Haematol"},{"key":"3494_CR34","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2018-11-884577","volume":"133","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhao AL, Duan MH, Li ZY, Cao XX, Feng J, Zhou DB, Zhong DR, Fajgenbaum DC, Li J (2019) Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood 133:1720\u20131728. https:\/\/doi.org\/10.1182\/blood-2018-11-884577","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03494-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-020-03494-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03494-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T14:07:44Z","timestamp":1622297264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-020-03494-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3494"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03494-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"15 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This single-center retrospective study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University. The need for informed consent was waived by the committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}